Harvard Bioscience, Inc. (NASDAQ:HBIO) Director George Uveges sold 35,054 shares of the business’s stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $4.61, for a total value of $161,598.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) traded up $0.20 during trading on Monday, reaching $4.80. The company’s stock had a trading volume of 144,131 shares, compared to its average volume of 167,103. The company has a market capitalization of $160.45, a PE ratio of -240.00 and a beta of 1.32. The company has a quick ratio of 1.87, a current ratio of 3.40 and a debt-to-equity ratio of 0.13. Harvard Bioscience, Inc. has a 52-week low of $2.25 and a 52-week high of $5.20.
Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings data on Thursday, March 1st. The medical instruments supplier reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. Harvard Bioscience had a positive return on equity of 2.38% and a negative net margin of 0.85%. The company had revenue of $27.46 million during the quarter, compared to analysts’ expectations of $26.60 million. analysts expect that Harvard Bioscience, Inc. will post 0.11 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in shares of Harvard Bioscience by 2,013.7% in the fourth quarter. Wells Fargo & Company MN now owns 32,446 shares of the medical instruments supplier’s stock valued at $107,000 after acquiring an additional 30,911 shares during the period. New York State Common Retirement Fund bought a new stake in shares of Harvard Bioscience in the third quarter valued at approximately $321,000. Northern Trust Corp boosted its position in shares of Harvard Bioscience by 5.2% in the second quarter. Northern Trust Corp now owns 86,205 shares of the medical instruments supplier’s stock valued at $220,000 after acquiring an additional 4,260 shares during the period. Algert Global LLC boosted its position in shares of Harvard Bioscience by 31.0% in the third quarter. Algert Global LLC now owns 149,094 shares of the medical instruments supplier’s stock valued at $559,000 after acquiring an additional 35,276 shares during the period. Finally, AXA boosted its position in shares of Harvard Bioscience by 16.7% in the fourth quarter. AXA now owns 167,500 shares of the medical instruments supplier’s stock valued at $553,000 after acquiring an additional 24,000 shares during the period. 63.54% of the stock is owned by institutional investors.
WARNING: “Harvard Bioscience, Inc. (HBIO) Director George Uveges Sells 35,054 Shares” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/03/12/harvard-bioscience-inc-hbio-director-george-uveges-sells-35054-shares.html.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.